Frontlight ResearchEarly access
TerminatedEarly phase 1
Safety and Efficacy of NK520 to Treat Pediatric Relapsed/Refractory Acute Myeloid Leukemia
Key facts
- Who runs it
- Base Therapeutics (Shanghai) Co., Ltd.
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Terminated
- Phase
- Early phase 1
- People taking part
- 2 people enrolled
- Started
- 1 Jul 2024
- Ended
- 1 Jan 2025
- Type of study
- Interventional, 3 groups
- Treatments tested
- NK520
- Record updated
- 30 September 2026
- Why it stopped
- poor accrual
Who can take part
- Age
- 6 years to 18 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 14 criteriaShow less
Who can take part
- Participants must be between 6 and 18 years
- Diagnostic Criteria: Meet the 2022 World Health Organization (WHO) diagnostic criteria for acute myelocytic leukemia (AML), unsuitable for current treatments or patients with relapsed/refractory AML after ≥2 lines of therapy. The definition of relapsed/refractory acute myeloid leukemia is based on the 2017 Chinese Guidelines for Diagnosis and Treatment: a. Relapsed AML: Diagnosis is confirmed when leukemia cells reappear in the peripheral blood or bone marrow blast cells exceed 5% after complete remission (CR) (excluding reasons such as bone marrow regeneration post-consolidation chemotherapy) or there is extramedullary infiltration by leukemia cells; b. Refractory AML: Initial cases unresponsive after two cycles of standard regimen treatment; recurrence within 12 months after CR and consolidation therapy; recurrence beyond 12 months with ineffectiveness of conventional chemotherapy; those who have relapsed twice or more; or persistent extramedullary leukemia
- For participants under 16 years old, Lansky performance status must be ≥50%; for participants aged 16 or older, Karnofsky performance status must be ≥50%
- Expected survival of at least 12 weeks
- Normal Organ Function
Who cannot take part
- Severe bleeding tendency or coagulation disorders, or currently receiving thrombolytic therapy
- Receipt of live attenuated vaccines within 2 weeks before the first dose or planned during the study period
- Participation in another clinical trial and receipt of investigational drug within 4 weeks prior to the first dose
- Receipt of immune-modulatory drugs (including thymosin, interferons, except for local use to manage conditions like pleural or ascites fluid) within 2 weeks before the first dose
- AML associated with congenital syndromes, such as Down syndrome, Fanconi anemia, Bloom syndrome, Kostmann syndrome, or congenital aplastic anemia
- Human immunodeficiency virus (HIV)-infected individuals, or individuals with known active syphilis infection
- Any other condition or situation in which the investigator deems the patient unsuitable for participation in this study
- At screening, positive hepatitis B or C viral markers as follows:; Hepatitis B surface antigen (HBsAg) positive with serum hepatitis B virus-deoxyribonucleic acid (HBV-DNA) level ≥1×10\^3 copies/mL or above normal range; Positive for hepatitis C virus (HCV) antibodies
- Acute promyelocytic leukemia, chronic myeloid leukemia, acute mixed lineage leukemia, or known central nervous system leukemia
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This study will evaluate the safety and efficacy of NK520 in the treatment of pediatric relapsed/refractory acute myeloid leukemia. NK520 will be administered by intravenous injection. The safety and efficacy of this treatment will be evaluated.
The 3 groups in the trial
- Group A(low-dose group)Treatment being tested
NK520: 5x10\^7 NK/kg
Treatment: NK520
- Group B(medium-dose group)Treatment being tested
NK520: 1.5×10\^8NK/kg
Treatment: NK520
- Group C(high-dose group)Treatment being tested
NK520: 3×10\^8NK/kg
Treatment: NK520
Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- An Open, Single Center Exploratory Study to Evaluate Safety and Efficacy of NK520 for Pediatric Patients With Relapsed/Refractory Acute Myeloid Leukemia
- Record updated
- 30 September 2026